Effects of impaired functional domains of osteopontin on renal crystal formation: Analyses of OPN transgenic and OPN knockout mice

Journal of Bone and Mineral Research

Volumn 25, Issue 12, 2010, Pages 2712-2723

  Hamamoto, Shuzo ^a   Nomura, Shintaro ^b   Yasui, Takahiro ^a   Okada, Atsushi ^a   Hirose, Masahiro ^a   Shimizu, Hideo ^a   Itoh, Yasunori ^a   Tozawa, Keiichi ^a   Kohri, Kenjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcium Binding Domains; Osteopontin; Renal Crystal Formation; RGD Sequence; Transgenic Mice

Indexed keywords

GLYOXYLIC ACID; OSTEOPONTIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CALCIUM BINDING; CONTROLLED STUDY; CRYSTAL STRUCTURE; IN VIVO STUDY; MALE; MICROPHOTOGRAPHY; MOUSE; NONHUMAN; SCANNING ELECTRON MICROSCOPY; TRANSGENE;

EID: 78649570143     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.090520     Document Type: Article

References (43)

1. Boyce WH., Organic matrix of human urinary concretions. Am J Med. 1968; 45: 673-683.
2. Ryall RL, Fleming DE, Grover PK, Chauvet M, Dean CJ, Marshall VR., The hole truth: intracrystalline proteins and calcium oxalate kidney stones. Mol Urol. 2000; 4: 391-402.
3. Fleming DE, Van Riessen A, Chauvet MC, et al. Intracrystalline proteins and urolithiasis: a synchrotron X-ray diffraction study of calcium oxalate monohydrate. J Bone Miner Res. 2003; 18: 1282-1291.
4. Konya E, Umekawa T, Iguchi M, Kurita T., The role of osteopontin on calcium oxalate crystal formation. Eur Urol. 2003; 43: 564-571.
5. Kohri K, Suzuki Y, Yoshida K, et al. Molecular cloning and sequencing of cDNA encoding urinary stone protein, which is identical to osteopontin. Biochem Biophys Res Commun. 1992; 184: 859-864.
6. Kohri K, Nomura S, Kitamura Y, et al. Structure and expression of the mRNA encoding urinary stone protein (osteopontin). J Biol Chem. 1993; 268: 15180-15184.
7. Chellaiah MA, Kizer N, Biswas R, et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell. 2003; 14: 173-189.
8. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J., Osteopontin-a molecule for all seasons. QJM. 2002; 95: 3-13.
9. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H., Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res. 2005; 96: 717-722.
10. Jansson M, Panoutsakopoulou V, Baker J, Klein L, Cantor H., Cutting edge: Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin- deficient mice. J Immunol. 2002; 168: 2096-2099.
11. Pepinsky RB, Mumford RA, Chen LL, et al. Comparative assessment of the ligand and metal ion binding properties of integrins alpha9beta1 and alpha4beta1. Biochemistry. 2002; 41: 7125-7141.
12. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000; 287: 860-864.
13. Weber GF, Ashkar S, Glimcher MJ, Cantor H., Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996; 271: 509-512.
14. Smith JW, Tachias K, Madison EL., Protein loop grafting to construct a variant of tissue-type plasminogen activator that binds platelet integrin αIIbβ3. J Biol Chem. 1995; 270: 30486-30490.
15. Denhardt DT, Guo X., Osteopontin: a protein with diverse functions. FASEB J. 1993; 7: 1475-1482.
16. Reinholt FP, Hultenby K, Oldberg A, Heinegard D., Osteopontin-a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A. 1990; 87: 4473-4475.
17. Nakamura I, Duong le T, Rodan SB, Rodan GA., Involvement of alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab. 2007; 25: 337-344.
18. Suzuki K, Zhu B, Rittling SR, et al. Colocalization of intracellular osteopontin with CD44 is associated with migration, cell, fusion, and resorption in osteoclasts. J Bone Miner Res. 2002; 17: 1486-1497.
19. Angelucci A, Festuccia C, D'Andrea G, Teti A, Bologna M., Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators. Biol Chem. 2002; 383: 229-234.
20. Kok DJ, Khan SR., Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int. 1994; 46: 847-854.
21. Lieske JC, Deganello S, Toback FG., Cell-crystal interactions and kidney stone formation. Nephron. 1999; 81: 8-17.
22. Yasui T, Fujita K, Asai K, Kohri K., Osteopontin regulates adhesion of calcium oxalate crystals to renal epithelial cells. Int J Urol. 2002; 9: 100-108.
23. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL., Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest. 1998; 101: 1468-1478.
24. Giachelli GM, Steitz S., Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 2000; 19: 615-622.
25. Sodek J, Ganss B, McKee MD., Osteopontin. Crit Rev Oral Biol Med. 2000; 11: 279-303.
26. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS., Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001; 107: 1055-1061.
27. Higashibata Y, Sakuma T, Kawahata H, et al. Identification of promoter regions involved in cell- and developmental stage-specific osteopontin expression in bone, kidney, placenta, and mammary gland: an analysis of transgenic mice. J Bone Miner Res. 2004; 19: 78-88.
28. Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y., 'Green mice' as a source of ubiquitous green cells. FEBS Lett. 1997; 407: 313-319.
29. Okada A, Nomura S, Higashibata Y, et al. Successful formation of calcium oxalate crystal deposition in mouse kidney by intraabdominal glyoxylate injection. Urol Res. 2007; 35: 89-99.
30. Pizzolato P., Histochemical recognition of calcium oxalate. J Histochem Cytochem. 1964; 12: 333-336.
31. Khan SR, Johnson JM, Peck AB, Cornelius JG, Glenton PA., Expression of osteopontin in rat kidneys: induction during ethylene glycol induced calcium oxalate nephrolithiasis. J Urol. 2002; 168: 1173-1181.
32. Takahashi S, Leiss M, Moser M, et al. The RGD motif in fibronection is essential for development but dispensable for fibril assembly. J Cell Biol. 2007; 178: 167-178.
33. Wesson JA, Johnson RJ, Mazzali M, et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol. 2003; 14: 139-147.
34. Mo L, Liaw L, Evan AP, Sommer AJ, Lieske JC, Wu XR., Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein or both. Am J Physiol Renal Physiol 2007; 293: 1935-1943.
35. Okada A, Nomura S, Saeki Y, et al. Morphological conversion of calcium oxalate crystals into stones is regulated by osteopontin in mouse kidney. J Bone Miner Res. 2008; 23: 1629-1637.
36. Lark MW, Stroup GB, Dodds RA, et al. Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat. J Bone Miner Res. 2001; 16: 319-327.
37. Yoshitake H, Rittling SR, Denhardt DT, Noda M., Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A. 1999; 96: 8156-8160.
38. Flores ME, Norgard M, Heingard, D, Reinholt FP, Andersson G, RGD-directed attachment of isolated rat osteoclasts to osteopontin, bone sialoprotein, and fibronectin. Exp Cell Res. 1992; 201: 526-530.
39. Ross FP, Chappel J, Alvarez JI, et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin αvβ3 protentiate bone resorption. J Biol Chem. 1993; 268: 9901-9907.
40. Asplin JR, Parks JH, Coe FL., Dependence of upper limit of metastablity on supersaturation in nephrolithiasis. Kidney Int. 1997; 52: 1602-1608.
41. Lopez CA, Hoyer JR, Wilson PD, Waterhouse P, Denhardt DT, Urinary macromolecular inhibition of crystal adhesion to renal epithelial cells is impaired in male stone formers. Kidney Int. 2005; 68: 1784-1792.
42. Lopez CA, Hoyer JR, Wilson PD, Waterhouse P, Denhardt DT., Heterogeneity of osteopontin expression among nephrons in mouse kidneys and enhanced expression in sclerotic glomeruli. Lab Invest. 1993; 69: 355-363.
43. Singh K, Deonarine D, Shanmugam V, et al. Calcium-binding properties of osteopontin derived from non-osteogenic sources. J Biochem. 1993; 114: 702-707.